The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.
Synonyms:
related_synonym:
(1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; CS 500; Compactin; ML 236 B; ML-236B; antibiotic ML 236B; mevastatina; mevastatine; mevastatinum
[Cholestyramine Resin co-treated with mevastatin] results in increased expression of and results in increased activity of AACS protein; mevastatin results in increased expression of and results in increased activity of AACS protein
mevastatin affects the expression of ABCA1 mRNA Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]] Mevastatin (compactin) decreases expression of abca1 mRNA in rat peripheral fibroblasts
[mevastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein promotes the reaction [mevastatin results in increased expression of CYP3A4 mRNA]
EIF2S1 protein modified form inhibits the reaction [mevastatin results in decreased expression of DDIT3 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of IDI1 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA]
mevastatin results in decreased phosphorylation of FOXO1 protein mevastatin results in increased phosphorylation of FOXO1 protein 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [mevastatin results in increased phosphorylation of FOXO1 protein]; FOXO1 protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [mevastatin results in increased phosphorylation of FOXO1 protein]
mevastatin results in increased expression of HMOX1 mRNA; mevastatin results in increased expression of HMOX1 protein 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [mevastatin results in increased expression of HMOX1 mRNA]; 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [mevastatin results in increased expression of HMOX1 protein]; acetovanillone inhibits the reaction [mevastatin results in increased expression of HMOX1 protein]; CYBB protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [mevastatin results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [mevastatin results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [mevastatin results in increased expression of HMOX1 protein]; diphenyleneiodonium inhibits the reaction [mevastatin results in increased expression of HMOX1 protein]; FOXO1 protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]; KEAP1 protein affects the reaction [mevastatin results in increased expression of HMOX1 mRNA]; KEAP1 protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]; MAPK14 protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]; MAPK8 protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]; mevastatin promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]; NCF1 protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [mevastatin results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [mevastatin results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [mevastatin results in increased expression of HMOX1 protein]
KEAP1 protein affects the reaction [mevastatin results in increased expression of HMOX1 mRNA]; KEAP1 protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]
Acetylcysteine inhibits the reaction [mevastatin results in increased phosphorylation of MAPK8 protein]; Edaravone inhibits the reaction [mevastatin results in increased phosphorylation of MAPK8 protein]; MAPK8 protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [mevastatin results in increased phosphorylation of MAPK8 protein]
mevastatin results in increased phosphorylation of MAPK9 protein Acetylcysteine inhibits the reaction [mevastatin results in increased phosphorylation of MAPK9 protein]; Edaravone inhibits the reaction [mevastatin results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [mevastatin results in increased phosphorylation of MAPK9 protein]
mevastatin results in increased expression of MSMO1 mRNA EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA]
mevastatin results in increased phosphorylation of NCF1 protein acetovanillone inhibits the reaction [mevastatin results in increased phosphorylation of NCF1 protein]; diphenyleneiodonium inhibits the reaction [mevastatin results in increased phosphorylation of NCF1 protein]; NCF1 protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]
mevastatin promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]; NFE2L2 protein affects the reaction [mevastatin results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [mevastatin results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [mevastatin results in increased phosphorylation of NFE2L2 protein]
[mevastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein promotes the reaction [mevastatin results in increased expression of CYP3A4 mRNA]
mevastatin results in decreased lipidation of RHOA protein Mevalonic Acid inhibits the reaction [mevastatin results in decreased lipidation of RHOA protein]
mevastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein]
mevastatin results in decreased expression of SREBF1 protein EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein]
mevastatin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; mevastatin inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein]; mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein]
browse the term
